Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions Victoria Johnson

Published Date: 14 Jan 2026

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

Read Full News

Latest News

FDA Grants Breakthrough Therapy Designation to Ianalumab, First Potential Sjögren’s Targeted Therapy Victoria Johnson

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus Chelsie Derman

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control Victoria Johnson

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

Q4 2025 Recap: Rheumatology News and Updates Victoria Johnson

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Todays Updates

Telemedicine Not Reaching Rural Psychiatric Patients

Telemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Todays Updates

Telemedicine Not Reaching Rural Psychiatric Patients

Telemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Latest News

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

News All Time

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles Chelsie Derman

New data links chronic pain to impaired muscle relaxation, with the greatest limitations observed in fibromyalgia and chronic tension-type headache.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial Alex Hillenbrand

A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.

High Rates of Overactive Bladder Found in Women With Fibromyalgia Chelsie Derman

Evidence shows fibromyalgia patients face higher overactive bladder rates and symptom severity, highlighting the importance of integrated care.

Febuxostat Lowers Serum Uric Acid More Effectively in Gout Patients With CKD Chelsie Derman

Multicenter study shows patients with both CKD and gout achieve better urate control on febuxostat than those with gout alone, despite the lower doses.

Unilateral Adrenalectomy for Primary Aldosteronism Linked to CKD, Gout Risks Chelsie Derman

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief Abigail Brooks, MA

In a phase 3 trial, the first-in-class triple agonist delivered up to an average of 71.2 lbs weight loss and reduced WOMAC pain scores for knee osteoarthritis.

Fear of Movement, Central Sensitization May Worsen Outcomes in Gout Chelsie Derman

Patients with gout frequently experience kinesiophobia and central sensitization, which were independently linked to greater pain intensity.

taVNS Reduces Pain, Improves Mood in Fibromyalgia Patients Chelsie Derman

New research shows both left and bilateral taVNS are safe, noninvasive treatment options that relieve pain in individuals with fibromyalgia.

GLPG3667 Meets Primary Endpoint in Dermatomyositis, Misses in SLE Phase 3 Trials Alex Hillenbrand

Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.

Dietary Diversity With Dairy, Fruit, Grains Linked to Lower Gout Risk Chelsie Derman

A large prospective cohort study showed that moderate dietary diversity, particularly greater intake of grains, dairy, vegetables, and fruits, is linked to reduced gout risk.

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia Chelsie Derman

Six weeks of freshly squeezed lemon juice diluted in water significantly reduced serum urate and improved kidney function in patients with gout and hyperuricemia.

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care Patrick Campbell

Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.

Psoriatic Arthritis in 2025: Year in Review Victoria Johnson

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Reframing Fibromyalgia Care in 2025: Restricted Impact of TNX-102 SL’s Approval Philip J. Mease, MD, Nicole Zangoglia, PT, DPT, Andrew Sharobeem, DO, FACR

New advances in fibromyalgia are part of a larger shift in pain management in 2025.

Fibromyalgia in 2025: Year in Review Victoria Johnson

The fibromyalgia year in review highlights FDA approvals, data, and advances in 2025.

Rheumatoid Arthritis in 2025: Year in Review Victoria Johnson

The rheumatoid arthritis year in review highlights FDA approvals, data, and advances in 2025.

Recommended News For You

As pesticides and wildfires rise, kids with cancer need resources

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

Advancing Health in Africa

DNA origami offers more accurate imaging in the fight against pancreatic cancer

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Stem Cell Selection Unneeded for SSc Transplant Therapy?

'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV

Recommended Articles For You

An Overview Of Leukemia Cutis: What It Is And How To Treat It 

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer 

Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide 

Intrapancreatic Fat, Pancreatitis, and Cancer: Role of Cancer-Associated Fibroblasts 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

2.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

3.

3D virtual staining technology enables non-invasive observation of cancer tissue

4.

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

5.

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

1.

Exploring the Unknown: Unveiling the Mysteries of GIST Tumors

2.

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life

3.

What Is A High MCV Level? Causes, Symptoms, And Treatment Options

4.

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion

5.

How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

4.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot